EUVIMEDEUVIMED entdecken
Klinische StudieOpen Access · CC BY 4.0

Development of cardiovascular risk factors in women with a BRCA1/2 pathogenic variant within five years after tubo-ovarian cancer risk reduction in the TUBA study

Tamar A Gootzen, Marleen M H J van Gelder, Rosella P M G Hermens, Majke H D van Bommel, Mirjam J A Apperloo, Marieke Arts-de Jong, Monique M A Brood-van Zanten, Sjors F P J Coppus, Jose Custers, Helena C van Doorn, Katja N Gaarenstroom, Marline G Harmsen und 14 weitere

Maturitas · 2026

DOI: 10.1016/j.maturitas.2026.108886 ↗

Kurz gefasst

Klinische Studie in der Zeitschrift Maturitas, 2026. Verfasst von Tamar A Gootzen und 25 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gynaecology and Obstetrics, Radboudumc, Geert Grooteplein Zuid 10, 6525 GA, Nijmegen, the Netherlands. Electronic address: tamar.gootze…. Hauptthemen laut MEDLINE: Cardiovascular Diseases, Fallopian Tube Neoplasms, Heart Disease Risk Factors, Ovarian Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Dutch Cancer Society.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVES: The effects of risk-reducing salpingo-oophorectomy on the development of cardiovascular risk factors in women with BRCA1/2 pathogenic variants are unknown. We compared the development of cardiovascular risk factors 5 years post-surgery between participants who had risk-reducing salpingo-oophorectomy with and without hormonal replacement therapy and participants who had risk-reducing salpingectomy. STUDY DESIGN: Eligible participants with a BRCA1/2 pathogenic variant from the TUBA study were longitudinally followed and categorized into three groups: (1) salpingectomy without subsequent oophorectomy within 5 years, (2) salpingo-oophorectomy with hormonal replacement therapy (use ≥3 years), (3) salpingo-oophorectomy without hormonal replacement therapy (use

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cardiovascular DiseasesFallopian Tube NeoplasmsHeart Disease Risk FactorsOvarian NeoplasmsSalpingectomySalpingo-oophorectomyAdultFemaleHumansMiddle AgedBRCA1 ProteinBRCA2 ProteinHormone Replacement TherapyLongitudinal StudiesOvariectomyRisk Factors

Stichwörter der Autor:innen

BRCA1BRCA2Cardiovascular riskHormonal replacement therapyOvarian cancerPrevention

Substanzen

BRCA1 ProteinBRCA1 protein, humanBRCA2 ProteinBRCA2 protein, human

Autor:innen und Institutionen

  • Department of Gynaecology and Obstetrics, Radboudumc, Geert Grooteplein Zuid 10, 6525 GA, Nijmegen, the Netherlands. Electronic address: tamar.gootzen@radboudumc.nl.
  • IQ Health, Radboudumc, Kapittelweg 54, 6525 EP, Nijmegen, the Netherlands. Electronic address: marleen.vangelder@radboudumc.nl.
  • IQ Health, Radboudumc, Kapittelweg 54, 6525 EP, Nijmegen, the Netherlands. Electronic address: rosella.hermens@radboudumc.nl.
  • Department of Gynaecology and Obstetrics, Radboudumc, Geert Grooteplein Zuid 10, 6525 GA, Nijmegen, the Netherlands. Electronic address: majke.vanbommel@radboudumc.nl.
  • Department of Obstetrics and Gynecology, Medical Centre Leeuwarden, Thialfweg 44, 8441 PW, Leeuwarden, the Netherlands. Electronic address: mirjam.apperloo@mcl.nl.
  • Department of Gynaecology and Obstetrics, Radboudumc, Geert Grooteplein Zuid 10, 6525 GA, Nijmegen, the Netherlands. Electronic address: Marieke.arts-dejong@radboudumc.nl.

Förderung

  • Dutch Cancer Society

Zitieren

APA

Gootzen, T. A., van Gelder, M. M. H. J., Hermens, R. P. M. G., van Bommel, M. H. D., Apperloo, M. J. A., Arts-de Jong, M., Zanten, M. M. A. B., Coppus, S. F. P. J., Custers, J., van Doorn, H. C., Gaarenstroom, K. N., Harmsen, M. G., Knippenberg, M., van Lonkhuijzen, L. R. C. W., Piek, J. M. J., Simons, M., Slangen, B. F. M., Tros, R., Vos, M. C., …, & de Hullu, J. A. (2026). Development of cardiovascular risk factors in women with a BRCA1/2 pathogenic variant within five years after tubo-ovarian cancer risk reduction in the TUBA study. Maturitas. https://doi.org/10.1016/j.maturitas.2026.108886

Vancouver

Gootzen TA, van Gelder MMHJ, Hermens RPMG, van Bommel MHD, Apperloo MJA, Arts-de Jong M, et al. Development of cardiovascular risk factors in women with a BRCA1/2 pathogenic variant within five years after tubo-ovarian cancer risk reduction in the TUBA study. Maturitas. 2026. doi:10.1016/j.maturitas.2026.108886

BibTeX
@article{Gootzen2026,
  author = {Gootzen, Tamar A and van Gelder, Marleen M H J and Hermens, Rosella P M G and van Bommel, Majke H D and Apperloo, Mirjam J A and Arts-de Jong, Marieke and Zanten, Monique M A Brood-van and Coppus, Sjors F P J and Custers, Jose and van Doorn, Helena C and Gaarenstroom, Katja N and Harmsen, Marline G and Knippenberg, Marjan and van Lonkhuijzen, Luc R C W and Piek, Jurgen M J and Simons, Michiel and Slangen, Brigitte F M and Tros, Rachel and Vos, M Caroline and Yigit, Refika and Zweemer, Ronald P and Hoogerbrugge, Nicoline and Kets, C Marleen and Maas, Angela H E M and Steenbeek, Miranda P and de Hullu, Joanne A},
  title = {Development of cardiovascular risk factors in women with a BRCA1/2 pathogenic variant within five years after tubo-ovarian cancer risk reduction in the TUBA study},
  journal = {Maturitas},
  year = {2026},
  doi = {10.1016/j.maturitas.2026.108886}
}
Kostenlos starten →